Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Betamipron 3-benzamidopropanoic acid

Synonyms: Betamipronum, SureCN605899, CHEMBL1231530, BSPBio_002628, CBDivE_001204, ...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of N-Benzoyl-beta-alanine

RESULTS: The clearance of panipenem and betamipron was correlated with creatinine clearance and the volume of the distribution of panipenem was correlated with body weight [1].
Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease [2].
During the fever episode, although bacteremia or fungemia was not evident despite frequent blood cultures, intravenous panipenem/betamipron (PAPM/BP) gradually resulted in decline of the fever [3].

High impact information on N-Benzoyl-beta-alanine

Panipenem/betamipron is well tolerated with few adverse events reported in clinical trials, most commonly elevated serum levels of hepatic transaminases and eosinophils, rash and diarrhoea [4].
Panipenem/betamipron was also effective in adults with surgical or gynaecological infections, and in paediatric patients with respiratory tract and urinary tract infections in noncomparative trials [4].
The K(i) value of probenecid for hOAT2 was 766 microM, whereas those of probenecid, KW-3902, and betamipron for hOAT4 were 54.9, 20.7, and 502 microM, respectively [5].
Diflunisal, ketoprofen, flurbiprofen, indomethacin, naproxen, and ibuprofen were equally or more effective (IC(50) = 0.85-8 microM) than probenecid or betamipron, two known potent inhibitors of hOAT1 (IC(50) = 8 and 6 microM, respectively) with in vivo nephroprotective effects [6].
In the phenotypic analysis of lymphocytes, there was a significant decrease of total and activated T cells after panipenem/betamipron (PAPM/BP) treatment (p<0.05) [7].

Chemical compound and disease context of N-Benzoyl-beta-alanine

The protective effects of betamipron (BP, N-benzoyl-beta-alanine) on the nephrotoxicity of cisplatin were examined as indicated by body weight gain, ratio of kidney weight to body weight, blood urea nitrogen and serum creatinine levels in tumor-bearing rats [8].

Biological context of N-Benzoyl-beta-alanine

Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats [8].

Analytical, diagnostic and therapeutic context of N-Benzoyl-beta-alanine

The pharmacokinetics of panipenem/betamipron were investigated in eight patients after a 1-h intravenous infusion of panipenem/betamipron (500 mg/500 mg) [2].

References

Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function. Tajima, N., Ishizuka, H., Naganuma, H. Chemotherapy. (2006) [Pubmed]
Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. Ohashi, N., Uematsu, T., Nagashima, S., Kanamaru, M., Tajima, N., Togawa, A., Hishida, A. J. Infect. Chemother. (2005) [Pubmed]
Infective endocarditis associated with quadricuspid aortic valve. Takeda, N., Ohtaki, E., Kasegawa, H., Tobaru, T., Sumiyoshi, T. Japanese heart journal. (2003) [Pubmed]
Panipenem/betamipron. Goa, K.L., Noble, S. Drugs (2003) [Pubmed]
Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. Enomoto, A., Takeda, M., Shimoda, M., Narikawa, S., Kobayashi, Y., Kobayashi, Y., Yamamoto, T., Sekine, T., Cha, S.H., Niwa, T., Endou, H. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. Mulato, A.S., Ho, E.S., Cihlar, T. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies. Nomura, S., Kagawa, H., Ozaki, Y., Nagahama, M., Yoshimura, C., Fukuhara, S. Thromb. Res. (1999) [Pubmed]
Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats. Tokunaga, J., Kobayashi, M., Kitagawa, A., Nakamura, C., Arimori, K., Nakano, M. Biol. Pharm. Bull. (1997) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.